1. Search Result
Search Result
Results for "

Pulmonary Emphysema

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

1

Biochemical Assay Reagents

3

Peptides

7

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P1645
    Papain
    10+ Cited Publications

    Cathepsin Cardiovascular Disease Inflammation/Immunology
    Papain is a cysteine protease of the peptidase C1 family. Papain enhances red cell agglutination by anti-D and anti-A, and increases red cell sensitivity to K cell-mediated lysis in ADCC assays. Papain can induce pulmonary emphysema. Papain can be used for the researches of Rh haemolytic disease of the newborn and pulmonary emphysema .
    Papain
  • HY-B2237
    Lysozyme from chicken egg white
    5+ Cited Publications

    Bacterial HIV Infection
    Lysozyme from chicken egg white is a bactericidal enzyme, and it lyses gram-positive bacteria. Lysozyme from chicken egg white can also be used for the research of HIV infection and pulmonary emphysema .
    Lysozyme from chicken egg white
  • HY-B2237A
    Lysozyme chloride
    5+ Cited Publications

    Bacterial HIV Infection
    Lysozyme chloride is a bactericidal enzyme, and it lyses gram-positive bacteria. Lysozyme chloride can also be used for the research of HIV infection and pulmonary emphysema .
    Lysozyme chloride
  • HY-P1645A

    Cathepsin Cardiovascular Disease Inflammation/Immunology
    Papain (1.5-10 units/mg) is a cysteine protease of the peptidase C1 family. Papain (1.5-10 units/mg) enhances red cell agglutination by anti-D and anti-A, and increases red cell sensitivity to K cell-mediated lysis in ADCC assays. Papain (1.5-10 units/mg) can induce pulmonary emphysema. Papain (1.5-10 units/mg) can be used for the researches of Rh haemolytic disease of the newborn and pulmonary emphysema .
    Papain (1.5-10 units/mg)
  • HY-124295

    ABT-301; MPT0E028; TMU-C-0012

    HDAC Akt Apoptosis Inflammation/Immunology Cancer
    Imofinostat (ABT-301; MPT0E028) is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively. Imofinostat has a weak inhibitory effect on HDAC8 (IC50 of 2.5 ​​μM), but no inhibitory effect on HDAC4 (IC50>10 μM). Imofinostat reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. Imofinostat has a broad-spectrum antitumor activity, including colorectal cancer, B-cell lymphoma, non-small cell lung carcinoma (NSCLC), and pancreatic cancer, while also showing therapeutic potential in non-tumor diseases like emphysema and pulmonary fibrosis .
    Imofinostat
  • HY-17428

    Histamine Receptor Neurological Disease Inflammation/Immunology
    Tripelennamine hydrochloride is a histamine H1-receptor antagonist. Tripelennamine hydrochloride effectively reverses histamine-induced bronchoconstriction, increased transpulmonary pressure, elevated pulmonary vascular resistance and reduced dynamic compliance. Tripelennamine hydrochloride does not significantly affect arterial hypoxemia, hemoglobin desaturation and hypercapnia in horses undergoing short-term high-intensity exercise. Tripelennamine hydrochloride exhibits local and central analgesic activity. Tripelennamine hydrochloride can be used in studies related to emphysema, urticaria and acute laminitis .
    Tripelennamine hydrochloride
  • HY-P1645B

    Cathepsin Cardiovascular Disease Inflammation/Immunology
    Papain (lyophilized powder, ≥10 units/mg protein) is a cysteine protease of the peptidase C1 family. Papain (lyophilized powder, ≥10 units/mg protein) enhances red cell agglutination by anti-D and anti-A, and increases red cell sensitivity to K cell-mediated lysis in ADCC assays. Papain (lyophilized powder, ≥10 units/mg protein) can induce pulmonary emphysema. Papain (lyophilized powder, ≥10 units/mg protein) can be used for the researches of Rh haemolytic disease of the newborn and pulmonary emphysema .
    Papain (lyophilized powder, ≥10 units/mg protein)
  • HY-P3293

    POL6014

    Elastase Inflammation/Immunology
    Lonodelestat (POL6014) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat (POL6014) has the potential for the research of cystic fibrosis (CF) .
    Lonodelestat
  • HY-P3293A

    POL6014 TFA

    Elastase Inflammation/Immunology
    Lonodelestat TFA (POL6014 TFA) is a potent, orally active and selective peptide inhibitor of human neutrophil elastase (hNE). Lonodelestat TFA has the potential for the research of cystic fibrosis (CF) .
    Lonodelestat TFA
  • HY-165407

    Elastase CFTR Inflammation/Immunology
    Neltenexine, a mucolytic agent, is an Elastase inhibitor. Neltenexine diminishes anion secretion in in bronchial epithelial cells by inhibiting the Cl− and HCO3- uptake via Na/K/2Cl++− and Na+/HCO3- cotransporter without blockade of the CFTR channel, and also diminishes anion secretion via stimulation of Cl−/HCO3- exchanger. Neltenexine significantly prevents pulmonary emphysema with a reduction of alveolar deformation in rat models induced by Elastase. Neltenexine can be used for lung diseases such as chronic obstructive pulmonary disease (COPD) research .
    Neltenexine
  • HY-138570

    Elastase Inflammation/Immunology
    HLE-IN-1 (Compound 4) is a human leukocyte elastase HLE inhibitor (Ki=1.8 nM). HLE-IN-1 is used in emphysema and inflammamry pulmonary research .
    HLE-IN-1
  • HY-167891

    Phosphodiesterase (PDE) Apoptosis Inflammation/Immunology
    GPD-1116 is an orally active Phosphodiesterase (PDE) 4 and PDE1 inhibitor. GPD-1116 can reduce smoke-induced apoptosis of lung cells. GPD-1116 is effective in several disease models in animals, including emphysema, acute lung injury, chronic obstructive pulmonary disease (COPD), asthma and pulmonary hypertension .
    GPD-1116
  • HY-17428A

    Histamine Receptor Neurological Disease Inflammation/Immunology
    Tripelennamine is a histamine H1-receptor antagonist. Tripelennamine effectively reverses histamine-induced bronchoconstriction, increased transpulmonary pressure, elevated pulmonary vascular resistance and reduced dynamic compliance. Tripelennamine does not significantly affect arterial hypoxemia, hemoglobin desaturation and hypercapnia in horses undergoing short-term high-intensity exercise. Tripelennamine exhibits local and central analgesic activity. Tripelennamine can be used in studies related to emphysema, urticaria and acute laminitis .
    Tripelennamine
  • HY-17428B

    Histamine Receptor Neurological Disease Inflammation/Immunology
    Tripelennamine citrate is a histamine H1-receptor antagonist. Tripelennamine citrate effectively reverses histamine-induced bronchoconstriction, increased transpulmonary pressure, elevated pulmonary vascular resistance and reduced dynamic compliance. Tripelennamine citrate does not significantly affect arterial hypoxemia, hemoglobin desaturation and hypercapnia in horses undergoing short-term high-intensity exercise. Tripelennamine citrate exhibits local and central analgesic activity. Tripelennamine citrate can be used in studies related to emphysema, urticaria and acute laminitis .
    Tripelennamine citrate
  • HY-17428R

    Reference Standards Histamine Receptor Neurological Disease Inflammation/Immunology
    Tripelennamine hydrochloride (Standard) is the analytical standard of Tripelennamine hydrochloride (HY-17428). This product is intended for research and analytical applications. Tripelennamine hydrochloride is a histamine H1-receptor antagonist. Tripelennamine hydrochloride effectively reverses histamine-induced bronchoconstriction, increased transpulmonary pressure, elevated pulmonary vascular resistance and reduced dynamic compliance. Tripelennamine hydrochloride does not significantly affect arterial hypoxemia, hemoglobin desaturation and hypercapnia in horses undergoing short-term high-intensity exercise. Tripelennamine hydrochloride exhibits local and central analgesic activity. Tripelennamine hydrochloride can be used in studies related to emphysema, urticaria and acute laminitis .
    Tripelennamine hydrochloride (Standard)
  • HY-P10854

    NF-κB Interleukin Related STAT Akt Neurological Disease Inflammation/Immunology
    TAT-N15 is a p55PIK inhibitor with remarkable anti-inflammatory activity and neuroprotective effects. TAT-N15 can significantly inhibit the activation of IL-6, IL-8, Akt, and NF-κB pathways, as well as suppress the protein expression of phosphorylated STAT3 and NF-κB. By inhibiting the activation of Akt, STAT3, and NF-κB pathways, TAT-N15 is used in research on acute conjunctivitis, allergic rhinitis, chronic obstructive pulmonary disease (COPD), and stroke .
    TAT-N15
  • HY-153149

    Adenosine Receptor Apoptosis PGC-1α Metabolic Disease Inflammation/Immunology
    LJ-2698 is an orally active adenosine A3 receptor antagonist. LJ-2698 induces increased levels of anti-inflammatory cytokines in macrophages and significantly elevates the number of anti-inflammatory M2 macrophages in the lung. LJ-2698 prevents alveolar cavity enlargement, restores pulmonary function, inhibits matrix metalloproteinase activity and pulmonary cell apoptosis in the lung tissues of mice. LJ-2698 prevents renal injury, inhibits renal lipid accumulation, and increases PGC1α levels in renal tissues of mice with diabetic nephropathy. LJ-2698 is applicable to the research of emphysema and diabetic nephropathy .
    LJ-2698
  • HY-E71363

    Cathepsin Cardiovascular Disease Inflammation/Immunology
    Papain (USP) refers to Papain (HY-P1645) that meets the standards of the US Pharmacopoeia. Papain is a cysteine protease of the peptidase C1 family. Papain enhances red cell agglutination by anti-D and anti-A, and increases red cell sensitivity to K cell-mediated lysis in ADCC assays. Papain can induce pulmonary emphysema. Papain can be used for the researches of Rh haemolytic disease of the newborn and pulmonary emphysema .
    papain (USP)
  • HY-181762

    Phosphodiesterase (PDE) TRP Channel NF-κB NOD-like Receptor (NLR) Interleukin Related Inflammation/Immunology
    Multitarget AD-IN-6 (Compound 39) is a multi-target inhibitor, with an IC50 of 15.54 μM against PDE4B, 15.15 μM against PDE7A, 8.39 μM against PDE3A, and a Kd of 37.7 μM against CHIT1. Multitarget AD-IN-6 acts as a TRPA1 antagonist, reduces the level of the NLRP3 inflammasome multiprotein complex to inhibit its activation, while inhibiting PDE4B, PDE7A and CHIT1, and decreasing the phosphorylation of NF-κB. Multitarget AD-IN-6 improves the pathology of elastase-induced emphysema in mice. Multitarget AD-IN-6 is applicable for the research of chronic obstructive pulmonary disease .
    Multitarget AD-IN-6

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: